Statins: how it works, status and trials

Approved (generic)PillLowering LDL cholesterol

Statins slow the liver's production of cholesterol. With less cholesterol inside, liver cells add more LDL receptors, which pull more LDL out of the blood.

In technical terms: Block the rate-limiting step of cholesterol synthesis. Lower liver cholesterol activates SREBP-2, which raises LDL-receptor (and PCSK9) production.

The highlighted badge marks where Statins acts. Open the full map or compare every therapy.

At a glance

Acts on: HMG-CoA reductase · liver
How it is given: Oral · daily
What the main trial found: LDL-C −30% to ≥50% by intensity; major vascular events ↓ ≈ 22% per mmol/L LDL-C
Status (curated October 25, 2026): Approved (generic)

Where it fits in the body

Cholesterol synthesis and absorption

When the liver has less cholesterol, whether because synthesis is blocked (statins, bempedoic acid) or less arrives from the gut (ezetimibe, bile acid sequestrants), SREBP-2 switches on the LDL-receptor gene and the liver pulls more LDL out of the blood. SREBP-2 also raises PCSK9, which is one reason PCSK9 inhibitors add well to statins.

See it on the interactive map

Evidence

CTT 2010 (PubMed 21067804)

Common questions

How does Statins work?

Statins slow the liver's production of cholesterol. With less cholesterol inside, liver cells add more LDL receptors, which pull more LDL out of the blood. In technical terms: Block the rate-limiting step of cholesterol synthesis. Lower liver cholesterol activates SREBP-2, which raises LDL-receptor (and PCSK9) production. It acts on HMG-CoA reductase · liver.

How much does Statins lower cholesterol or other lipids?

LDL-C −30% to ≥50% by intensity; major vascular events ↓ ≈ 22% per mmol/L LDL-C. Individual results differ, and a clinician can say what to expect for one person.

Is Statins approved, and what is the status?

Approved (generic) (curated October 25, 2026).

How is Statins taken?

Oral · daily.

Related therapies

Bempedoic acid (Nexletol, Nexlizet): Approved 2020
Ezetimibe (Zetia): Approved (generic)
Bile acid sequestrants (colesevelam): Approved (generic)
Evolocumab (Repatha) and alirocumab (Praluent): Approved 2015

Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.